126 related articles for article (PubMed ID: 28361034)
1. Combinatorial Ranking of Gene Sets to Predict Disease Relapse: The Retinoic Acid Pathway in Early Prostate Cancer.
Nim HT; Furtado MB; Ramialison M; Boyd SE
Front Oncol; 2017; 7():30. PubMed ID: 28361034
[TBL] [Abstract][Full Text] [Related]
2. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
3. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
4. Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the
Cangiano M; Grudniewska M; Salji MJ; Nykter M; Jenster G; Urbanucci A; Granchi Z; Janssen B; Hamilton G; Leung HY; Beumer IJ
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925994
[TBL] [Abstract][Full Text] [Related]
5. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
[TBL] [Abstract][Full Text] [Related]
6. Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas.
Liu S; Wang W; Zhao Y; Liang K; Huang Y
Front Oncol; 2020; 10():809. PubMed ID: 32547947
[No Abstract] [Full Text] [Related]
7. Elevated MRE11 expression associated with progression and poor outcome in prostate cancer.
Wang J; Xu WH; Wei Y; Zhu Y; Qin XJ; Zhang HL; Ye DW
J Cancer; 2019; 10(18):4333-4340. PubMed ID: 31413753
[No Abstract] [Full Text] [Related]
8. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
9. Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.
Seidensaal K; Nollert A; Feige AH; Muller M; Fleming T; Gunkel N; Zaoui K; Grabe N; Weichert W; Weber KJ; Plinkert P; Simon C; Hess J
Mol Cancer; 2015 Dec; 14():204. PubMed ID: 26634247
[TBL] [Abstract][Full Text] [Related]
10. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.
Meng J; Wang LH; Zou CL; Dai SM; Zhang J; Lu Y
Med Sci Monit; 2017 Oct; 23():5176-5183. PubMed ID: 29084195
[TBL] [Abstract][Full Text] [Related]
11. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
[No Abstract] [Full Text] [Related]
12. Decreased Expression of NUSAP1 Predicts Poor Overall Survival in Cervical Cancer.
Xie Q; Ou-Yang W; Zhang M; Wang H; Yue Q
J Cancer; 2020; 11(10):2852-2863. PubMed ID: 32226503
[No Abstract] [Full Text] [Related]
13. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine.
Arshi A; Sharim J; Park DY; Park HY; Yazdanshenas H; Bernthal NM; Shamie AN
Spine J; 2017 May; 17(5):645-655. PubMed ID: 27856382
[TBL] [Abstract][Full Text] [Related]
14. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data.
Xu N; Wu YP; Ke ZB; Liang YC; Cai H; Su WT; Tao X; Chen SH; Zheng QS; Wei Y; Xue XY
J Transl Med; 2019 Sep; 17(1):311. PubMed ID: 31533842
[TBL] [Abstract][Full Text] [Related]
15. Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis.
Zhang Y; Yang W; Li D; Yang JY; Guan R; Yang MQ
BMC Med Genomics; 2018 Nov; 11(Suppl 5):104. PubMed ID: 30454048
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
17. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer.
Kim H; Lapointe J; Kaygusuz G; Ong DE; Li C; van de Rijn M; Brooks JD; Pollack JR
Cancer Res; 2005 Sep; 65(18):8118-24. PubMed ID: 16166285
[TBL] [Abstract][Full Text] [Related]
18. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
19. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.
Song BN; Kim SK; Chu IS
Exp Mol Med; 2017 Jan; 49(1):e282. PubMed ID: 28082741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
